| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected and Quantified |
|---|
| Creation Date | 2007-05-30 12:04:10 UTC |
|---|
| Update Date | 2022-09-22 18:34:55 UTC |
|---|
| HMDB ID | HMDB0006695 |
|---|
| Secondary Accession Numbers | - HMDB0029018
- HMDB06695
- HMDB29018
|
|---|
| Metabolite Identification |
|---|
| Common Name | Prolylhydroxyproline |
|---|
| Description | Prolylhydroxyproline is a dipeptide. Prolylhydroxyproline is a marker of bone collagen degradation, showing high sensitivity for the diagnosis of osteoporosis. Prolylhydroxyproline has been suggested as a possible alternative to hydroxyproline determination in bone resorption studies. Prolylhydroxyproline is one of the iminodipeptides present in the urine of patients with prolidase deficiency. Prolidase (X-Pro dipeptidase EC 3.4.13.9) splits iminodipeptides containing C-terminal proline or hydroxyproline (X-Pro or X-Hyp) to X+Pro or X+Hyp. Prolidase deficiency is a rare autosomal recessive disease characterized by chronic ulcerative dermatitis and mental retardation. These patients excrete large amounts of iminodipeptides containing C-terminal proline in the urine due to hereditary prolidase deficiency (PMID: 12636053 , 11863289 , 2387877 , 1874885 , 9586797 ). |
|---|
| Structure | O[C@@H]1C[C@H](N(C1)C(=O)[C@@H]1CCCN1)C(O)=O InChI=1S/C10H16N2O4/c13-6-4-8(10(15)16)12(5-6)9(14)7-2-1-3-11-7/h6-8,11,13H,1-5H2,(H,15,16)/t6-,7+,8+/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| L-Pro-L-hyp | ChEBI | | L-Prolyl-L-hydroxyproline | ChEBI | | (4R)-L-Prolyl-4-hydroxy-L-proline | HMDB | | 4-Hydroxy-1-L-prolyl-proline | HMDB | | L-4-Hydroxy-1-L-prolyl-proline | HMDB | | Proline-hydroxyproline | HMDB | | trans-4-Hydroxy-1-L-prolyl-proline | HMDB | | Prolylhydroxyproline | ChEBI | | Pro-hydroxy-Pro | HMDB | | Pro-Hyp | HMDB | | Proline hydroxyproline dipeptide | HMDB | | Proline-hydroxyproline dipeptide | HMDB |
|
|---|
| Chemical Formula | C10H16N2O4 |
|---|
| Average Molecular Weight | 228.245 |
|---|
| Monoisotopic Molecular Weight | 228.11100701 |
|---|
| IUPAC Name | (2S,4R)-4-hydroxy-1-[(2S)-pyrrolidine-2-carbonyl]pyrrolidine-2-carboxylic acid |
|---|
| Traditional Name | proline-hydroxyproline |
|---|
| CAS Registry Number | 18684-24-7 |
|---|
| SMILES | O[C@@H]1C[C@H](N(C1)C(=O)[C@@H]1CCCN1)C(O)=O |
|---|
| InChI Identifier | InChI=1S/C10H16N2O4/c13-6-4-8(10(15)16)12(5-6)9(14)7-2-1-3-11-7/h6-8,11,13H,1-5H2,(H,15,16)/t6-,7+,8+/m1/s1 |
|---|
| InChI Key | ONPXCLZMBSJLSP-CSMHCCOUSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic acids and derivatives |
|---|
| Class | Carboxylic acids and derivatives |
|---|
| Sub Class | Amino acids, peptides, and analogues |
|---|
| Direct Parent | Dipeptides |
|---|
| Alternative Parents | |
|---|
| Substituents | - Alpha-dipeptide
- N-acyl-alpha-amino acid
- N-acyl-alpha amino acid or derivatives
- Proline or derivatives
- N-acyl-l-alpha-amino acid
- Alpha-amino acid amide
- Alpha-amino acid or derivatives
- N-acylpyrrolidine
- Pyrrolidine carboxylic acid
- Pyrrolidine carboxylic acid or derivatives
- Pyrrolidine-2-carboxamide
- Tertiary carboxylic acid amide
- Pyrrolidine
- Secondary alcohol
- Amino acid
- Amino acid or derivatives
- Carboxamide group
- Secondary amine
- Azacycle
- Organoheterocyclic compound
- Carboxylic acid
- Secondary aliphatic amine
- Monocarboxylic acid or derivatives
- Hydrocarbon derivative
- Organopnictogen compound
- Organic oxide
- Alcohol
- Organonitrogen compound
- Carbonyl group
- Organooxygen compound
- Amine
- Organic nitrogen compound
- Organic oxygen compound
- Aliphatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aliphatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Not Available | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 1.44 minutes | 32390414 | | Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 1.96 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 8.8068 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 6.99 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 387.7 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 418.0 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 243.6 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 62.7 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 164.7 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 45.2 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 272.5 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 247.0 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 840.6 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 547.7 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 45.9 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 716.8 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 183.0 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 217.9 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 764.2 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 535.5 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 334.2 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Prolylhydroxyproline,1TMS,isomer #1 | C[Si](C)(C)O[C@@H]1C[C@@H](C(=O)O)N(C(=O)[C@@H]2CCCN2)C1 | 2141.1 | Semi standard non polar | 33892256 | | Prolylhydroxyproline,1TMS,isomer #2 | C[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1 | 2078.7 | Semi standard non polar | 33892256 | | Prolylhydroxyproline,1TMS,isomer #3 | C[Si](C)(C)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)O | 2036.4 | Semi standard non polar | 33892256 | | Prolylhydroxyproline,2TMS,isomer #1 | C[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O[Si](C)(C)C)CN1C(=O)[C@@H]1CCCN1 | 2144.4 | Semi standard non polar | 33892256 | | Prolylhydroxyproline,2TMS,isomer #2 | C[Si](C)(C)O[C@@H]1C[C@@H](C(=O)O)N(C(=O)[C@@H]2CCCN2[Si](C)(C)C)C1 | 2084.6 | Semi standard non polar | 33892256 | | Prolylhydroxyproline,2TMS,isomer #3 | C[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1[Si](C)(C)C | 2062.6 | Semi standard non polar | 33892256 | | Prolylhydroxyproline,3TMS,isomer #1 | C[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O[Si](C)(C)C)CN1C(=O)[C@@H]1CCCN1[Si](C)(C)C | 2152.3 | Semi standard non polar | 33892256 | | Prolylhydroxyproline,3TMS,isomer #1 | C[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O[Si](C)(C)C)CN1C(=O)[C@@H]1CCCN1[Si](C)(C)C | 2224.4 | Standard non polar | 33892256 | | Prolylhydroxyproline,3TMS,isomer #1 | C[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O[Si](C)(C)C)CN1C(=O)[C@@H]1CCCN1[Si](C)(C)C | 2678.3 | Standard polar | 33892256 | | Prolylhydroxyproline,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@@H]1C[C@@H](C(=O)O)N(C(=O)[C@@H]2CCCN2)C1 | 2372.8 | Semi standard non polar | 33892256 | | Prolylhydroxyproline,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1 | 2332.0 | Semi standard non polar | 33892256 | | Prolylhydroxyproline,1TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)O | 2303.9 | Semi standard non polar | 33892256 | | Prolylhydroxyproline,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O[Si](C)(C)C(C)(C)C)CN1C(=O)[C@@H]1CCCN1 | 2599.9 | Semi standard non polar | 33892256 | | Prolylhydroxyproline,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)O[C@@H]1C[C@@H](C(=O)O)N(C(=O)[C@@H]2CCCN2[Si](C)(C)C(C)(C)C)C1 | 2582.5 | Semi standard non polar | 33892256 | | Prolylhydroxyproline,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1[Si](C)(C)C(C)(C)C | 2546.4 | Semi standard non polar | 33892256 | | Prolylhydroxyproline,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O[Si](C)(C)C(C)(C)C)CN1C(=O)[C@@H]1CCCN1[Si](C)(C)C(C)(C)C | 2830.1 | Semi standard non polar | 33892256 | | Prolylhydroxyproline,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O[Si](C)(C)C(C)(C)C)CN1C(=O)[C@@H]1CCCN1[Si](C)(C)C(C)(C)C | 2799.3 | Standard non polar | 33892256 | | Prolylhydroxyproline,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O[Si](C)(C)C(C)(C)C)CN1C(=O)[C@@H]1CCCN1[Si](C)(C)C(C)(C)C | 2970.4 | Standard polar | 33892256 |
|
|---|
| Spectra |
|---|
| |
|---|
| Biological Properties |
|---|
| Cellular Locations | Not Available |
|---|
| Biospecimen Locations | - Blood
- Cerebrospinal Fluid (CSF)
- Sweat
- Urine
|
|---|
| Tissue Locations | |
|---|
| Pathways | |
|---|
| Normal Concentrations |
|---|
| |
| Blood | Expected but not Quantified | Not Quantified | Not Specified | Not Specified | Normal | | details | | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.87 +/- 1.0 uM | Adult (>18 years old) | Both | Normal | | details | | Urine | Detected and Quantified | 4.8-9.4 umol/mmol creatinine | Adult (>18 years old) | Female | Normal | | details | | Urine | Detected and Quantified | 4.5-7.7 umol/mmol creatinine | Adult (>18 years old) | Male | Normal | | details | | Urine | Detected and Quantified | 2.4-25.6 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details |
|
|---|
| Abnormal Concentrations |
|---|
| |
| Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.086 +/- 0.016 uM | Adult (>18 years old) | Both | Alzheimer's disease | | details | | Sweat | Detected but not Quantified | Not Quantified | Infant (0-1 year old) | Not Specified | screen-positive CF | | details | | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Female | Epithelial ovarian cancer | | details |
|
|---|
| Associated Disorders and Diseases |
|---|
| Disease References | | Alzheimer's disease |
|---|
- Fonteh AN, Harrington RJ, Tsai A, Liao P, Harrington MG: Free amino acid and dipeptide changes in the body fluids from Alzheimer's disease subjects. Amino Acids. 2007 Feb;32(2):213-24. Epub 2006 Oct 10. [PubMed:17031479 ]
| | Cystic fibrosis |
|---|
- Adriana Nori de Macedo. Robust capillary electrophoresis methods for biomarker discovery and routine measurements in clinical and epidemiological applications. March 2017 [Link]
|
|
|---|
| Associated OMIM IDs | |
|---|
| External Links |
|---|
| DrugBank ID | Not Available |
|---|
| Phenol Explorer Compound ID | Not Available |
|---|
| FooDB ID | FDB024028 |
|---|
| KNApSAcK ID | Not Available |
|---|
| Chemspider ID | 10077215 |
|---|
| KEGG Compound ID | Not Available |
|---|
| BioCyc ID | Not Available |
|---|
| BiGG ID | Not Available |
|---|
| Wikipedia Link | Not Available |
|---|
| METLIN ID | Not Available |
|---|
| PubChem Compound | 11902892 |
|---|
| PDB ID | Not Available |
|---|
| ChEBI ID | 74767 |
|---|
| Food Biomarker Ontology | Not Available |
|---|
| VMH ID | Not Available |
|---|
| MarkerDB ID | MDB00000488 |
|---|
| Good Scents ID | Not Available |
|---|
| References |
|---|
| Synthesis Reference | ustova, V.; Blaha, Karel. Amino acids and peptides. CXXVI. Dipeptides containing proline and 4-hydroxyproline. Collection of Czechoslovak Chemical Communications (1975), 40(3), 662-9. |
|---|
| Material Safety Data Sheet (MSDS) | Not Available |
|---|
| General References | - Husek P, Pohlidal A, Slabik D: Rapid screening of urinary proline-hydroxyproline dipeptide in bone turnover studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Feb 5;767(1):169-74. [PubMed:11863289 ]
- Pohlidal A, Husek P, Palicka V, Slabik D, Hill M, Matucha P: Novel and traditional biomarkers of bone turnover in postmenopausal women. Clin Chem Lab Med. 2003 Jan;41(1):74-8. [PubMed:12636053 ]
- Sugahara K, Kodama H: Liquid chromatography-mass spectrometry for simultaneous analyses of iminodipeptides containing an N-terminal or a C-terminal proline. J Chromatogr. 1991 Apr 19;565(1-2):408-15. [PubMed:1874885 ]
- Kodama H, Nakamura H, Sugahara K, Numajiri Y: Liquid chromatography-mass spectrometry for the qualitative analyses of iminodipeptides in the urine of patients with prolidase deficiency. J Chromatogr. 1990 May 18;527(2):279-88. [PubMed:2387877 ]
- Zhang J, Sugahara K, Yasuda K, Kodama H, Sagara Y, Kodama H: The effects of serum iminodipeptides and prednisolone on superoxide generation and tyrosyl phosphorylation of proteins in neutrophils from a patient with prolidase deficiency. Free Radic Biol Med. 1998 Mar 15;24(5):689-98. [PubMed:9586797 ]
- Lowry M, Hall DE, Brosnan JT: Metabolism of glycine- and hydroxyproline-containing peptides by the isolated perfused rat kidney. Biochem J. 1985 Jul 15;229(2):545-9. [PubMed:4038280 ]
- Kawaguchi T, Nanbu PN, Kurokawa M: Distribution of prolylhydroxyproline and its metabolites after oral administration in rats. Biol Pharm Bull. 2012;35(3):422-7. [PubMed:22382331 ]
- Lampiaho K, Nikkari T, Pikkarainen J, Karkkainen J, Kulonen E: Unexpected occurrence of prolylhydroxyproline during the analysis of collagen-bound carbohydrates by gas-liquid chromatography. J Chromatogr. 1972 Feb 2;64(2):211-8. [PubMed:5013106 ]
- Bienenstock HKIBRICK AC: Urinary excretion of prolylhydroxyproline in rheumatic diseases. Ann Rheum Dis. 1969 Jan;28(1):28-30. [PubMed:5305862 ]
- Codini M, Palmerini CA, Fini C, Lucarelli C, Floridi A: High-performance liquid chromatographic method for the determination of prolyl peptides in urine. J Chromatogr. 1991 Jan 4;536(1-2):337-41. [PubMed:2050773 ]
- KIBRICK AC, HASHIRO CQ, SCHULTZ RS, WALTERS MI, MILHORAT AT: PROLYLHYDROXYPROLINE IN URINE: ITS DETERMINATION AND OBSERVATIONS IN MUSCULAR DYSTROPHY. Clin Chim Acta. 1964 Oct;10:344-51. [PubMed:14219579 ]
- Hueckel HJ, Rogers QR: Prolylhydroxyproline absorption in hamsters. Can J Biochem. 1972 Jul;50(7):782-90. [PubMed:5050935 ]
- Kibrick AC, Power HL, Sevendal E, Milhorat AT: Prolylhydroxyproline in urine: improved method for detecting radioactivity with a scanner on full sheets of chromatography paper. Anal Biochem. 1968 Oct 24;25(1):40-5. [PubMed:5704756 ]
- KIBRICK AC, HASHIRO CQ, WALTERS MI, MILHORAT AT: DIKETOPIPERAZINE OF PROLYLHYDROXYPROLINE IN NORMAL HUMAN URINE. Proc Soc Exp Biol Med. 1965 Jan;118:62-4. [PubMed:14254586 ]
- Zhang A, Sun H, Han Y, Yuan Y, Wang P, Song G, Yuan X, Zhang M, Xie N, Wang X: Exploratory urinary metabolic biomarkers and pathways using UPLC-Q-TOF-HDMS coupled with pattern recognition approach. Analyst. 2012 Sep 21;137(18):4200-8. doi: 10.1039/c2an35780a. Epub 2012 Jul 31. [PubMed:22852134 ]
- Elshenawy S, Pinney SE, Stuart T, Doulias PT, Zura G, Parry S, Elovitz MA, Bennett MJ, Bansal A, Strauss JF 3rd, Ischiropoulos H, Simmons RA: The Metabolomic Signature of the Placenta in Spontaneous Preterm Birth. Int J Mol Sci. 2020 Feb 4;21(3). pii: ijms21031043. doi: 10.3390/ijms21031043. [PubMed:32033212 ]
|
|---|